Sung H, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

Article  CAS  PubMed  Google Scholar 

Arnold M, et al. Current and future burden of breast cancer: global Statistics for 2020 and 2040. The Breast. 2022;66:15–23. https://doi.org/10.1016/j.breast.2022.08.010.

Article  PubMed  PubMed Central  Google Scholar 

Bray F, et al. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.

Article  PubMed  Google Scholar 

Kaplan HG, Malmgren JA, Atwood MK, Calip GS. Effect of treatment and mammography detection on breast cancer survival over time: 1990–2007. Cancer. 2015;121(15):2553–61. https://doi.org/10.1002/cncr.29371.

Article  PubMed  Google Scholar 

Hashim D, et al. The global decrease in cancer mortality: trends and disparities. Ann Oncol. 2016;27(5):926–33. https://doi.org/10.1093/annonc/mdw027.

Article  CAS  PubMed  Google Scholar 

Feng Y, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and Molecular Pathogenesis. Genes Dis. 2018;5(2):77–106. https://doi.org/10.1016/j.gendis.2018.05.001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Testa U, Castelli G, Pelosi E. Breast cancer: a molecularly heterogenous disease needing subtype-specific treatments. Med Sci. 2020;8(1):18. https://doi.org/10.3390/medsci8010018.

Article  CAS  Google Scholar 

Beňačka R, Szabóová D, Guľašová Z, Hertelyová Z, Radoňák J. Classic and new markers in diagnostics and classification of breast cancer. Cancers. 2022;14(21):5444. https://doi.org/10.3390/cancers14215444.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kutasovic JR, McCart Reed AE, Sokolova A, Lakhani SR, Simpson PT. Morphologic and genomic heterogeneity in the evolution and progression of breast cancer. Cancers. 2020;12(4):848. https://doi.org/10.3390/cancers12040848.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Velaga R, Toi M. Advances in molecular medicine for breast cancer practice: a narrative review. Ann Breast Surg. 2023;7:38–38. https://doi.org/10.21037/abs-21-64.

Article  Google Scholar 

Lüönd F, Tiede S, Christofori G. Breast cancer as an example of tumor heterogeneity and tumor cell plasticity during malignant progression. Br J Cancer. 2021;125(2):164–75. https://doi.org/10.1038/s41416-021-01328-7.

Article  PubMed  PubMed Central  Google Scholar 

Postow MA, et al. Nivolumab and Ipilimumab versus Ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17. https://doi.org/10.1056/nejmoa1414428.

Article  PubMed  PubMed Central  Google Scholar 

Ribas A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315(15):1600. https://doi.org/10.1001/jama.2016.4059.

Article  CAS  PubMed  Google Scholar 

Hamid O, et al. Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma. N Engl J Med. 2013;369(2):134–44. https://doi.org/10.1056/nejmoa1305133.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hellmann MD, et al. Nivolumab plus ipilimumab in non–small-cell lung cancer. N Engl J Med. 2020;382(9):874–5. https://doi.org/10.1056/nejmc1916859.

Article  Google Scholar 

Garon EB, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28. https://doi.org/10.1056/nejmoa1501824.

Article  PubMed  Google Scholar 

Brahmer J, et al. Nivolumab versus Docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373(2):123–35. https://doi.org/10.1056/nejmoa1504627.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Z, et al. Low mutation and neoantigen burden and fewer effector tumor infiltrating lymphocytes correlate with breast cancer metastasization to lymph nodes. Sci Rep. 2019. https://doi.org/10.1038/s41598-018-36319-x.

Article  PubMed  PubMed Central  Google Scholar 

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.

Article  CAS  PubMed  Google Scholar 

Kim IS, et al. Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms. Nat Cell Biol. 2019;21(9):1113–26. https://doi.org/10.1038/s41556-019-0373-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med. 2014;211(8):1503–23. https://doi.org/10.1084/jem.20140692.

Article  CAS  PubMed  PubMed Central  Google Scholar 

DeLeon-Pennell KY, Barker TH, Lindsey ML. Fibroblasts: the arbiters of extracellular matrix remodeling. Matrix Biol. 2020;91–92:1–7. https://doi.org/10.1016/j.matbio.2020.05.006.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salemme V, Centonze G, Cavallo F, Defilippi P, Conti L. The crosstalk between tumor cells and the immune microenvironment in breast cancer: implications for immunotherapy. Front Oncol. 2021. https://doi.org/10.3389/fonc.2021.610303.

Article  PubMed  PubMed Central  Google Scholar 

Allison E, Edirimanne S, Matthews J, Fuller SJ. Breast cancer survival outcomes and tumor-associated macrophage markers: a systematic review and meta-analysis. Oncol Ther. 2022;11(1):27–48. https://doi.org/10.1007/s40487-022-00214-3.

Article  PubMed  PubMed Central  Google Scholar 

Munir MT, et al. Tumor-associated macrophages as multifaceted regulators of breast tumor growth. Int J Mol Sci. 2021;22(12):6526. https://doi.org/10.3390/ijms22126526.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhardwaj V, Ansell SM. Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies. Front Cell Develop Biol. 2023. https://doi.org/10.3389/fcell.2023.1129343.

Article  Google Scholar 

Wu F, et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Trans Targeted Ther. 2021. https://doi.org/10.1038/s41392-021-00641-0.

Article  Google Scholar 

Peng D, et al. Myeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL6/STAT3 and no/notch cross-talk signaling. Can Res. 2016;76(11):3156–65. https://doi.org/10.1158/0008-5472.can-15-2528.

Article  CAS  Google Scholar 

Chen L, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017;9(6):7204–18. https://doi.org/10.18632/oncotarget.23208.

Article  PubMed  PubMed Central  Google Scholar 

Dvorak HF. Tumors: wounds that do not heal—redux. Cancer Immunol Res. 2015;3(1):1–11. https://doi.org/10.1158/2326-6066.cir-14-0209.